Cytosorbents Corporation
CTSO
$0.79
$0.045.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.35M | 33.48M | 32.71M | 32.97M | 29.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.35M | 33.48M | 32.71M | 32.97M | 29.85M |
| Cost of Revenue | 7.89M | 8.43M | 7.97M | 7.56M | 6.34M |
| Gross Profit | 26.46M | 25.05M | 24.74M | 25.40M | 23.51M |
| SG&A Expenses | 35.84M | 35.59M | 34.98M | 35.83M | 37.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.88M | 50.07M | 49.25M | 50.28M | 53.36M |
| Operating Income | -14.52M | -16.59M | -16.55M | -17.32M | -23.51M |
| Income Before Tax | -12.68M | -11.87M | -18.12M | -22.73M | -20.54M |
| Income Tax Expenses | -2.09M | -1.69M | -1.69M | -1.69M | -813.70K |
| Earnings from Continuing Operations | -10.59 | -10.18 | -16.42 | -21.03 | -19.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.59M | -10.18M | -16.42M | -21.03M | -19.73M |
| EBIT | -14.52M | -16.59M | -16.55M | -17.32M | -23.51M |
| EBITDA | -13.00M | -15.05M | -15.00M | -15.74M | -21.94M |
| EPS Basic | -0.19 | -0.19 | -0.30 | -0.39 | -0.38 |
| Normalized Basic EPS | -0.14 | -0.14 | -0.21 | -0.26 | -0.26 |
| EPS Diluted | -0.19 | -0.19 | -0.30 | -0.39 | -0.38 |
| Normalized Diluted EPS | -0.14 | -0.14 | -0.21 | -0.26 | -0.26 |
| Average Basic Shares Outstanding | 240.81M | 232.51M | 224.21M | 217.91M | 209.75M |
| Average Diluted Shares Outstanding | 245.37M | 237.07M | 224.21M | 217.91M | 209.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |